- Home
- KRON vs ATNM Comparison
KRON vs ATNM Comparison
Compare KRON & ATNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KRON
- ATNM
- Stock Information
- Founded
- KRON 2017
- ATNM 2000
- Country
- KRON United States
- ATNM United States
- Employees
- KRON N/A
- ATNM 37
- Industry
- KRON Medicinal Chemicals and Botanical Products
- ATNM Biotechnology: Pharmaceutical Preparations
- Sector
- KRON Health Care
- ATNM Health Care
- Exchange
- KRON Nasdaq
- ATNM Nasdaq
- Market Cap
- KRON 54.4M
- ATNM 48.4M
- IPO Year
- KRON 2020
- ATNM N/A
- Fundamental
- Price
- KRON $0.72
- ATNM $1.48
- Analyst Decision
- KRON Buy
- ATNM Strong Buy
- Analyst Count
- KRON 3
- ATNM 4
- Target Price
- KRON $1.63
- ATNM $8.75
- AVG Volume (30 Days)
- KRON 790.8K
- ATNM 344.7K
- Earning Date
- KRON 05-20-2025
- ATNM 05-16-2025
- Dividend Yield
- KRON N/A
- ATNM N/A
- EPS Growth
- KRON N/A
- ATNM N/A
- EPS
- KRON N/A
- ATNM N/A
- Revenue
- KRON $9,848,000.00
- ATNM N/A
- Revenue This Year
- KRON N/A
- ATNM N/A
- Revenue Next Year
- KRON N/A
- ATNM N/A
- P/E Ratio
- KRON N/A
- ATNM N/A
- Revenue Growth
- KRON 56.62
- ATNM N/A
- 52 Week Low
- KRON $0.67
- ATNM $1.03
- 52 Week High
- KRON $1.60
- ATNM $10.24
- Technical
- Relative Strength Index (RSI)
- KRON 35.81
- ATNM 55.71
- Support Level
- KRON $0.67
- ATNM $1.35
- Resistance Level
- KRON $0.76
- ATNM $1.64
- Average True Range (ATR)
- KRON 0.05
- ATNM 0.15
- MACD
- KRON -0.01
- ATNM 0.01
- Stochastic Oscillator
- KRON 19.69
- ATNM 62.70
About KRON Kronos Bio Inc.
Kronos Bio Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery and development of small molecule therapeutics to address deregulated transcription, a hallmark of cancer and autoimmune diseases.
About ATNM Actinium Pharmaceuticals Inc. (Delaware)
Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of radiotherapies for patients with cancers lacking effective treatment options. The company's proprietary technology platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest to kill those cells safely and effectively. Its product candidates are Iomab-B, an antibody-drug construct containing iodine 131 (I-131), used for hematopoietic stem cells transplantation in various indications, and Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), currently in human clinical trials for acute myeloid leukemia.